Combination of gemcitabine-containing magnetoliposome and oxaliplatin-containing magnetoliposome in breast cancer treatment: A possible mechanism with potential for clinical application

Abstract

Breast cancer is a major global health problem with high incidence and case fatality rates. The use of magnetoliposomes has been suggested as an effective therapeutic approach because of their good specificity for cancers. In this study, we developed two novel magnetoliposomes, namely, Gemcitabine-containing magnetoliposome (GML) and Oxaliplatin-containing magnetoliposome (OML). These magnetoliposomes were combined (CGOML) was used to treat breast cancer under an external magnetic field. Biosafety test results showed that GML and OML were biologically safe to blood cells and did not adversely affect the behavior of mice. Pharmacokinetic and tissue distribution studies indicated that both magnetoliposomes exhibited stable structures and persisted at the target area under an external magnetic field. Cell and animal experiments revealed that CGOML can markedly suppress the growth of MCF-7 cells, and only the CGOML group can minimize the tumor size among all the groups. Finally, CGOML can significantly inhibit MCF-7cell growth both in vitro and vivo by activating the apoptotic signaling pathway of MCF-7 cells.

Liposomes Loaded with Cisplatin and Magnetic Nanoparticles: Physicochemical Characterization, Pharmacokinetics, and In-Vitro Efficacy

“…Although encapsulating water-soluble magnetite nanoparticle cores and anticancer drugs in liposomes has been proposed by several researchers [ 17 , 18 ], this strategy is hindered by limitations on the encapsulation efficiency and thermal disruption of the membrane. Regarding encapsulation efficiency, the presence of many nanoparticles represents a large volume, which then reduces the space available for the encapsulation of the drug.…”

GLUT1-mediated selective tumor targeting with fluorine containing platinum(II) glycoconjugates

“…Oxaliplatin has been widely used in clinical application for the treatment of different types of cancer, such as colon cancer, urothelial cancer, and breast cancer. It can achieve better prognosis and improve life quality [ 39 , 40 ]. However, it may cause severe side effects including hyperalgesia, motor dysfunctions and peripheral neuropathy [ 4 , 41 , 42 ], which partially originated from a lack of tumor selectivity.…”

Hybrid Nanosystems for Biomedical Applications

“…Architectures for hybrid nanosystems. (A) Inorganic-liposome hybrid with nanoparticles incorporated within the liposome. ,− , (B) Cell membrane-coated nanoparticles. ,,, (C) Liposome with surface-associated nanoscale metals . (D) Functionalized polymer-coated metal nanoparticle .…”

“…The superparamagnetic properties of IONPs provide active drug targeting capabilities to liposomes by application of an external magnetic field, and these “magnetoliposomes” are widely successful as DDSs . Magnetic targeting improves magnetoliposomal DOX delivery efficacy in comparison to both liposomal and free DOX. − Magnetoliposomes have also been utilized to delivered curcumin, docetaxel, gemcitabine, cisplatin, and cuphen and have been reported effective for radical scavenging as well as treatment of diverse cancers. ,− Magnetoliposome-mediated chemotherapy can be further enhanced through active targeting ligands and moieties with endogenous stimulus sensitivity. ,,, Finally, one report describes a IONP/liposome-based docetaxel delivery system that displayed drug release in response to both an external magnetic field as well as NIR . As such, the development of magnetoliposomes has been a boon for targeted drug delivery.…”